Benzinga | Aug 6, 2020 08:14AM EDT

Wedbush Maintains Outperform on bluebird bio, Lowers Price Target to $81

Wedbush maintains bluebird bio (NASDAQ:BLUE) with a Outperform and lowers the price target from $89 to $81.